on Jun 4,2019
Philadelphia, June 4th, 2019 – CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to …
Read Storyon Feb 8,2019
Feldan Therapeutics is proud to unveil its new corporate identity! This new visual highlights the company's commitment to the therapeutic development of the Feldan Shuttle technology, an innovation developed in-house …
Read Storyon Dec 5,2018
Congratulations to Francois-Thomas Michaud for winning the “Visionary Entrepreneur of the Year” Award given by the CCIQ Chambre de commerce et d’industrie de Québec. Congratulations to Feldan Therapeutics’s team for …
Read Storyon Nov 27,2018
Québec City, Canada, November 27, 2018 – Feldan Therapeutics (hereafter “Feldan”), a preclinical biotechnology company specialized in the intracellular delivery of therapeutic proteins and peptides, has announced an investment of …
Read Storyon Nov 14,2018
We are proud partner of the CRISPR congress 2019 to be held in Québec City, June 17-20, 2019. This annual event provides an international forum for scientists and organizations interested …
Read Storyon Oct 12,2018
Quebec City, Canada, October 12, 2018 – David Guay, Research Director of Feldan Therapeutics (hereafter “Feldan”) announced that his collaborator, Dr. Paul McCray from the University of Iowa Carver College …
Read Storyon Sep 18,2018
QUÉBEC CITY, Sept. 18, 2018 /CNW Telbec/ - Feldan Therapeutics (hereafter "Feldan") has announced the closing of a $12.5 millions Series A financing round led by GC (parent company of …
Read Storyon Jun 27,2018
Seoul (South Korea) & Québec City (Canada) June 27, 2018 – GC LabCell (hereafter “GCLC”) and Feldan Therapeutics (hereafter “Feldan”) announced an agreement today granting GCLC exclusive rights to use …
Read Storyon Jun 4,2018
Our CEO François-Thomas Michaud and Strategic development director Vincent Menard are pleased to be in Boston this week for the BIO convention. They are looking forward to meeting with international …
Read Storyon May 29,2018
QUEBEC CITY, May 29, 2018 - Feldan Therapeutics, Inc. announced today the issuance of a new patent related to the refinement of the Feldan Shuttle platform. This technology, a peptide-based …
Read Story
2666, Boul. du Parc Technologique, Suite 290
Quebec, Qc, Canada,
G1P 4S6
Phone: 1-418-872-7277
Email: info@feldan.com